Aprea Therapeutics, Inc.
APRE
$0.79
-$0.04-5.22%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -10.88% | 16.40% | 15.17% | 21.44% | 6.66% |
| Total Depreciation and Amortization | 5.56% | 0.00% | 0.00% | 0.00% | 1.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -39.60% | -45.19% | 80.65% | -35.32% | 23.81% |
| Change in Net Operating Assets | 426.90% | 244.27% | 5.72% | -128.76% | 79.67% |
| Cash from Operations | -4.73% | 24.08% | 15.65% | -28.48% | 14.03% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 25.09% | 59,188.51% | 2,892.40% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -16,261.07% | -13,861.76% | -5,707.81% | -1,350.00% | 29.38% |
| Cash from Financing | -603.43% | 61,950.36% | 2,758.33% | 29,925.00% | 1,924.17% |
| Foreign Exchange rate Adjustments | -126.92% | -121.43% | 105.28% | -102.43% | 154.17% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -90.74% | 991.66% | 125.92% | -15.10% | 25.35% |